Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'CA088-1007: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safe... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of L... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'CO45042: A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasi... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Du... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-la... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safe... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safe... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Role of glucagon-like peptide 1 receptor Agonist (GLP1 RA) Dulaglutide on cerebral hemodynamics I... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the eff... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab ... Read More